



		EMLc	ATC codes: <a href="#">P01CB01</a>
Indication	Mucocutaneous leishmaniasis	ICD11 code: <a href="#">1F54.2</a>	
Medicine type	Chemical agent		
List type	Core (EML) (EMLc)		
Formulations	Parenteral > General injections > IM: 1.5 g per 5 mL in 5 mL ampoule		
EML status history	First added in 1987 ( <a href="#">TRS 770</a> ) Changed in 1989 ( <a href="#">TRS 796</a> ) Changed in 2002 ( <a href="#">TRS 914</a> ) Changed in 2007 ( <a href="#">TRS 950</a> ) Changed in 2009 ( <a href="#">TRS 958</a> ) Changed in 2023 ( <a href="#">TRS 1049</a> )		
Sex	All		
Age	Also recommended for children		
Therapeutic alternatives	The recommendation is for this specific medicine		
Patent information	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> .		
Wikipedia	<a href="#">Meglumine antimoniate</a>		
DrugBank	<a href="#">Meglumine antimoniate (Pentavalent Antimony)</a>		

## Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the listing for sodium stibogluconate / meglumine antimoniate on the EML and EMLc be amended to list each medicine separately with updated dosage form descriptions as follows: Sodium stibogluconate: Injection: 100 mg/mL in 30 mL vial Meglumine antimoniate: Injection: 1.5 g/5 mL in 5 mL ampoule

